Akanda (AKAN) Competitors $1.27 -0.07 (-5.51%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$1.31 +0.04 (+3.15%) As of 06/13/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock AKAN vs. ACXP, GTBP, PRTG, SLXN, OBSV, CHRO, CVM, APLM, MYNZ, and PMCBShould you be buying Akanda stock or one of its competitors? The main competitors of Akanda include Acurx Pharmaceuticals (ACXP), GT Biopharma (GTBP), Portage Biotech (PRTG), Silexion Therapeutics (SLXN), ObsEva (OBSV), Chromocell Therapeutics (CHRO), CEL-SCI (CVM), Apollomics (APLM), Mainz Biomed (MYNZ), and PharmaCyte Biotech (PMCB). These companies are all part of the "pharmaceutical products" industry. Akanda vs. Its Competitors Acurx Pharmaceuticals GT Biopharma Portage Biotech Silexion Therapeutics ObsEva Chromocell Therapeutics CEL-SCI Apollomics Mainz Biomed PharmaCyte Biotech Acurx Pharmaceuticals (NASDAQ:ACXP) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation and community ranking. Which has stronger earnings and valuation, ACXP or AKAN? Acurx Pharmaceuticals has higher earnings, but lower revenue than Akanda. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcurx PharmaceuticalsN/AN/A-$14.58M-$0.70-0.44Akanda$836.66K2.17-$32.28MN/AN/A Does the MarketBeat Community prefer ACXP or AKAN? Acurx Pharmaceuticals received 17 more outperform votes than Akanda when rated by MarketBeat users. CompanyUnderperformOutperformAcurx PharmaceuticalsOutperform Votes1794.44% Underperform Votes15.56%AkandaN/AN/A Does the media favor ACXP or AKAN? In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 2 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 0.62 beat Akanda's score of 0.24 indicating that Acurx Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Acurx Pharmaceuticals Positive Akanda Neutral Which has more volatility and risk, ACXP or AKAN? Acurx Pharmaceuticals has a beta of -1.38, suggesting that its share price is 238% less volatile than the S&P 500. Comparatively, Akanda has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ACXP or AKAN? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is ACXP or AKAN more profitable? Akanda's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Acurx PharmaceuticalsN/A -392.36% -223.78% Akanda N/A N/A N/A Do analysts rate ACXP or AKAN? Acurx Pharmaceuticals currently has a consensus price target of $8.00, indicating a potential upside of 2,522.95%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Akanda.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Akanda 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAcurx Pharmaceuticals beats Akanda on 8 of the 12 factors compared between the two stocks. Get Akanda News Delivered to You Automatically Sign up to receive the latest news and ratings for AKAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKAN vs. The Competition Export to ExcelMetricAkandaMedicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.81M$1.23B$5.57B$8.51BDividend YieldN/AN/A5.27%4.16%P/E RatioN/A12.7826.7519.65Price / Sales2.1710.32404.17152.18Price / CashN/A10.4038.2534.64Price / Book-0.021.446.964.59Net Income-$32.28M-$56.07M$3.23B$248.23M7 Day Performance-6.62%-4.50%-1.22%-1.07%1 Month Performance8.55%-1.71%6.34%2.59%1 Year Performance-73.54%-33.95%33.05%13.50% Akanda Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKANAkandaN/A$1.27-5.5%N/A-73.5%$1.81M$836.66K0.00110Short Interest ↓Gap DownACXPAcurx Pharmaceuticals3.2208 of 5 stars$0.35+4.2%$8.00+2,192.3%-87.4%$8.20MN/A-0.323Gap UpGTBPGT Biopharma2.6397 of 5 stars$3.10+2.6%$11.00+255.0%-1.7%$8.15MN/A-0.558Short Interest ↑Gap UpPRTGPortage Biotech1.0764 of 5 stars$8.01+5.3%N/A+22.3%$8.10MN/A-0.196Positive NewsShort Interest ↓SLXNSilexion TherapeuticsN/A$0.93-0.7%$5.00+438.8%N/A$8.08MN/A0.00N/AUpcoming EarningsOBSVObsEvaN/AN/AN/AN/A$7.94M$20.11M-0.1150CHROChromocell Therapeutics1.1661 of 5 stars$1.15-5.4%N/A-5.7%$7.91MN/A-0.974Short Interest ↓CVMCEL-SCI0.0781 of 5 stars$2.48-2.6%N/A-94.2%$7.50MN/A-5.1643APLMApollomics1.2333 of 5 stars$6.47-0.5%N/A-68.0%$7.43M$1.22M0.0045Negative NewsGap DownMYNZMainz Biomed2.6013 of 5 stars$2.09+1.5%$14.00+569.5%-92.7%$7.29M$893.99K-0.0330Gap UpPMCBPharmaCyte Biotech1.2265 of 5 stars$1.06+3.9%N/A-53.9%$7.28MN/A2.004Positive NewsShort Interest ↑ Related Companies and Tools Related Companies ACXP Competitors GTBP Competitors PRTG Competitors SLXN Competitors OBSV Competitors CHRO Competitors CVM Competitors APLM Competitors MYNZ Competitors PMCB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKAN) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akanda Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akanda With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKAN Stock Free AKAN Stock Alerts